Navigation Links
Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer
Date:3/25/2008

YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, March 25 /PRNewswire-FirstCall/ -- Galil Medical, a global cryotherapy company, today announced that Martin J. Emerson has been appointed President and Chief Executive Officer. Galil Medical is a market leader in cryotherapy technology for the minimally invasive treatment of cancerous and non-cancerous tumours. Mr. Emerson is an experienced and successful medical device industry executive, and was most recently President and CEO of American Medical Systems (AMS). He will be replacing Chen Barir, who will continue to serve on the Galil Medical Board of Directors.

Chen Barir commented, "Galil Medical is very pleased to have been able to attract an executive with the leadership experience and stature of Marty Emerson. We are confident that Marty will be able to help Galil Medical sustain the growth that has been recorded since our December 2006 reorganisation and recapitalisation financing."

"I am very excited to be joining Galil Medical," said Mr. Emerson. "The company has developed innovative cryotherapy solutions to treat prostate cancer and renal tumours and has a promising product pipeline for the Women's Health and Interventional Radiology markets. I look forward to working with the talented team to expand the opportunities for Galil Medical's industry leading technology around the globe."

Mr. Emerson has a strong track record of over 20 years of accomplishments in the medical device industry, most recently as President and Chief Executive Officer of AMS. During his tenure at AMS, he held executive roles including Vice President and General Manager of International, Executive Vice President of Global Sales and Marketing and Chief Operating Officer. Prior to joining AMS, he held senior roles in the overseas operations for several American-based companies including Baxter International and Boston Scientific.

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilising a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumours while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumours while protecting adjacent structures.

Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ: ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit http://www.galilmedical.com

Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

pam.schwartz@galilmedical.com


'/>"/>
SOURCE Galil Medical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BioCentury Conference
2. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
3. Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization
4. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
5. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
6. BioMS Medical Announces 2007 Year End Results
7. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
8. GHI Medical Deploys New Test to Help Determine Hair Loss
9. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):